KemPharm Inc. (NASDAQ:KMPH) shares traded down 8.1% during mid-day trading on Wednesday . The stock traded as low as $4.67 and last traded at $4.78, with a volume of 75,905 shares traded. The stock had previously closed at $5.20.

Several research analysts recently issued reports on the stock. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of KemPharm in a research report on Saturday, May 14th. Canaccord Genuity reiterated a “buy” rating on shares of KemPharm in a research report on Saturday, May 14th. Royal Bank Of Canada reiterated a “buy” rating on shares of KemPharm in a research report on Sunday, May 8th. Finally, Zacks Investment Research lowered shares of KemPharm from a “hold” rating to a “sell” rating in a research report on Wednesday, May 4th.

The firm’s market capitalization is $69.42 million. The firm has a 50 day moving average of $4.31 and a 200-day moving average of $9.87.

KemPharm (NASDAQ:KMPH) last released its quarterly earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.58) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.94) by $0.36. On average, analysts anticipate that KemPharm Inc. will post ($1.72) EPS for the current fiscal year.

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.